Cilengitide

CAS No. 188968-51-6

Cilengitide ( EMD 121974 )

Catalog No. M12961 CAS No. 188968-51-6

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 58 In Stock
5MG 87 In Stock
10MG 147 In Stock
25MG 259 In Stock
50MG 417 In Stock
100MG 599 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cilengitide
  • Note
    Research use only, not for human use.
  • Brief Description
    Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
  • Description
    Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
  • Synonyms
    EMD 121974
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    αVβ3 integrin; αVβ5 integrin
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    188968-51-6
  • Formula Weight
    588.66
  • Molecular Formula
    C27H40N8O7
  • Purity
    >98%(HPLC)
  • Solubility
    Water: 8 mg/mL (13.59 mM); DMSO: 100 mg/mL (169.87 mM)
  • SMILES
    CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Reardon DA, et al. Genes Y, 2011, 2(12):1159-1165.
molnova catalog
related products
  • MK-0429

    MK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay.

  • Vedolizumab

    Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

  • Lifitegrast

    A potent LFA-1/ICAM-1 antagonist with IC50 of 9 nM in HuT78 cells; exhibits good in vitro safety profile and low potency on CYP3A4, CYP2C9 and hERG.